Dear Colleague: Our community has been through a lot over the past two years, and all of us are looking forward to resuming our normal habits and routines. We are excited to see everyone in person at iSRS 2022 in the historical city center of Nantes, France. The iSRS symposium series has a long and treasured history of providing valued interaction between colleagues throughout the world. Program development is being guided by a team of internationally respected leaders within the field. This conference aims to address original research in all aspects of radiopharmaceutical science; synthesis, in vitro and ex vivo studies, in vivo biodistribution or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The iSRS 2022 Program Committee and I are pleased to announce that we received over 400 complete abstract submissions. We appreciate all who submitted and regard this as a good number, given current COVID-19 realities. COVID-19 and iSRS 2022 (the latest information) French COVID-19 restrictions are being progressively lifted, and the government is talking about the suppression of the vaccination passes by mid-March, if the decrease in the number of cases continues. We are assuming that by May all restrictions will be lifted. So far, all European citizens can travel within the EU without any restriction. But people must ensure before traveling that they comply with the rules imposed by airline and train companies. From the French government and updated frequently: https://www.diplomatie.gouv.fr/en/coming-to-france/coming-to-france-your-covid-19-questions-answered/ We are very much looking forward to a successful return to an in-person iSRS symposium! REGISTRATION (early registration ends march 31): here Stay tuned for iSRS 2022 updates. Sincerely, Sandrine Huclier iSRS 2022 Program Chair...
Lire plus »
ICOA conference in march 2022 : thursday 24/03 at 10:45 IRD amphitheatre Dr Sébastien VIDAL (ICSN, Gyf-sur Yvette) « Supramolecular Glycosciences and Applications » Contact: Marie-Aude HIEBEL and Vincent ROY ICOA – UMR 7311 / Université d’Orléans rue de Chartres B.P. 6759 – F-45067 Orléans Cedex 2, France mailto: vincent.roy@univ-orleans.fr / marie-aude.hiebel@univ-orleans.fr tel: + 33 (0)2 38 49 45 72 / + 33 (0)2 38 49 45...
Lire plus »
Dear Colleagues, Our community has been through a lot over the past year, and all of us are looking forward to resuming our normal habits and routines. We are excited to see everyone in person at iSRS 2022 in the historical city center of Nantes, France. The iSRS symposium series has a long and treasured history of providing valued interaction between colleagues throughout the world. Program development is being guided by a team of internationally respected leaders within the field. This conference aims to address original research in all aspects of radiopharmaceutical science; synthesis, in vitro and ex vivo studies, in vivo biodistribution or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. LATE-BREAKING ABSTRACT SUBMISSION: here (closed on feb 4 2022) REGISTRATION: here Stay tuned for iSRS 2022 updates. Sincerely, Sandrine Huclier iSRS 2022 Program Chair iSRS 2022 Promo Video iSRS 2022 Promotional...
Lire plus »
ISI NucMed: Interdisciplinary School In Nuclear Medicine Thematic school in nuclear medicine From monday 27 to wednesday 29 june 2022 in Nantes, France Over three days, 35 participants (Master/PhD students, post-docs, junior doctors and researchers) will deepen their knowledge in three main fields of nuclear medicine research, with a focus on astatine-211 radionuclide. They have the opportunity to meet some of the best international experts in radionuclide production, artificial intelligence for medical image analysis, and theranostic approaches. Program Registration mandatory (no registration fees) More...
Lire plus »
Dear Colleague, Our community has been through a lot over the past year, and all of us are looking forward to resuming our normal habits and routines. We are excited to see everyone in person at iSRS 2022 in the historical city center of Nantes, France. The iSRS symposium series has a long and treasured history of providing valued interaction between colleagues throughout the world. Program development is being guided by a team of internationally respected leaders within the field. This conference aims to address original research in all aspects of radiopharmaceutical science; synthesis, in vitro and ex vivo studies, in vivo biodistribution or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. ABSTRACT SUBMISSION: here (closed on december 6, 2021) REGISTRATION: here iSRS 2022 updates. Sincerely, Sandrine Huclier iSRS 2022 Program Chair iSRS 2022 Promo Video iSRS 2022 Promotional...
Lire plus »
Nantes research on astatine in the spotligh Astatine (At) is the rarest chemical element on Earth, and its 211 isotope is very promising for applications in targeted radiotherapy of cancers. Progress in this approach depends on a better understanding of the chemistry of At. Researchers from the CRCINA, Subatech and CEISAM laboratories have published a 15-year review of their work in the prestigious Accounts of Chemical Research journal. The most fundamental studies have made it possible to establish the nature of astatine’s stable species in water (Pourbaix diagram) and to reveal astatine ability to form so-called halogen bonds, i.e. specific and very directional attractive interactions. Thanks to a collaboration with the European Organization for Nuclear Research (CERN – Switzerland), the electron affinity of astatine was successfully determined, which is essential to better understand its chemical behaviour. The production of astatine-211 by the ARRONAX cyclotron has also enabled the development of new radiochemical synthesis methods and a real leap forward in its use in cancer therapy. The Pays de la Loire region has been supporting this work since 2005; it has also benefited from funding from the Programme d’Investissements d’Avenir (IRON and ArronaxPlus projects) and from the SIRIC ILIAD, placing Nantes as the main world player in astatine research. This recognition is distinguished at the European level by the creation of an international clinical network (NOAR COST action) which aims to demonstrate that astatine-211 can become the European standard for the treatment of some cancerous pathologies. Guérard, F., Maingueneau, C., Liu, L., Eychenne, R., Gestin, J.-F., Montavon, G. & Galland, N. Advances in the Chemistry of Astatine and Implications for the Development of Radiopharmaceuticals. Acc. Chem. Res. 54, 3264–3275 (2021) https://doi.org/10.1021/acs.accounts.1c00327 Read the interview of François Guérard and Nicolas Galland (CNRS, december...
Lire plus »
